🇺🇸

Distress Insolvency

· daily

US Corporate Distress Financial Stress SEC Filings — April 20, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream, a stark dichotomy emerges: 12 filings signal acute distress via bankruptcies (Charles & Colvard, QVC Group/Inc.), delisting notices (QVC stocks/notes, Armlogi, IT Tech Packaging, Nocera, OneMedNet), compliance failures, and waivers (FMC Corp leverage covenant), while 28 highlight resilience through M&A (QXO-TopBuild $17B, USA Rare Earth-Serra Verde $2.8B/SVRE, Sila Realty-Blue Owl $2.4B), financings ($58.5M Sidus, $50M Allbirds convertible), and expansions (Centrus, US Energy). Period-over-period trends are sparse but reveal mixed pressures: Alaska Air revenue +5% YoY to $3.3B but operating loss widened 42% YoY to $279M on +17% fuel costs; Limoneira Q2 FY2026 impairment $9.3M. No broad insider selling patterns, but capital allocation shifts to debt facilities/suspensions (US Energy ELOC halt) indicate liquidity focus over returns. Forward catalysts cluster in Q3 2026 (multiple M&A closings) amid Nasdaq/NYSE compliance deadlines through Oct 2026. Portfolio implication: Distressed M&A premiums (19-25%) offer alpha in building products/REITs/rare earths, but equity wipeouts in bankruptcies demand avoidance; monitor 8 compliance cures for short-term volatility.

48 high priority 48 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 17, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream (33 new), acute distress signals dominate with Chapter 11 prepacks by QVC Group ($2.9B credit + $2.15B notes accelerated, equity cancellation expected) and Cumulus Media ($600M debt elimination approved), plus Marizyme's Assignment for Benefit of Creditors (full asset transfer). Six small-caps (Global Interactive, Mustang Bio, Avalon GloboCare, VerifyMe, Terra Innovatum) face Nasdaq deficiencies for late 10-Ks or sub-$1 bids over 30 days, with 180-day compliance windows to Oct 2026. Counter-trends include debt refinancings (Emergent Bio: maturity to 2031, -200bps interest; AMC: 12.75% notes to 10.5% term loan +4yrs; InvenTrust: $250M notes at 5.44% avg) providing liquidity relief. No aggregate YoY/QoQ revenue/margin trends available, but restructuring themes signal leverage overload in media/retail/tech. Implications: Short equities in bankruptcies/delisting risks; favor post-reorg debt/equity in prepacks; monitor Oct catalysts for volatility.

43 high priority 43 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — April 17, 2026

Four companies announced insolvency proceedings on or around April 16-17, 2026, highlighting acute distress in consumer retail (QVC affiliates) and media/biotech sectors amid broader economic pressures. QVC Group and QVC Inc., affiliates, initiated prepackaged Chapter 11 filings in Texas with strong creditor support (>75% for RCF Claims, >55% for QVC Notes) but face $6.55B in accelerated debt ($2.9B credit, $2.15B notes, $1.5B debentures) and equity cancellation, signaling total shareholder wipeout. Cumulus Media secured court approval for its prepackaged plan to eliminate $600M debt pending FCC nod, offering relative outperformance via quicker deleveraging. Marizyme opted for Florida state-law Assignment for Benefit of Creditors, liquidating assets with no operational continuity implied. No period-over-period financial trends disclosed across filings, but inherent distress implies prior YoY revenue/margin declines leading to insolvency; portfolio-level pattern shows 3/4 pursuing prepackaged restructurings for ~90-day emergence, favoring creditors over equity. Market implications: heightened speculation risk, delistings, and short opportunities in consumer/media names.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 16, 2026

Across 37 filings in the USA Corporate Distress & Bankruptcy stream, acute distress signals are limited to covenant breaches (Katapult's 10th waiver) and Nasdaq delisting risks (Fathom), but the dominant theme is aggressive liquidity accumulation via $5B+ in combined equity/debt raises, facility expansions, and refinancings, suggesting pre-emptive balance sheet fortifications amid potential sector headwinds. Standout period growth includes CareDx's Q1 revenue +39% YoY to $118M (Testing Services +48% YoY), Lincoln Educational's student starts +19-20% Q1 2026, contrasting Katapult's origination/charge-off defaults. Biotech leads capital inflows (Spyre $463M, Achieve $354M, TeraWulf $1.036B), while ABS issuances (GM $1.27B, Toyota $1.9B, BMW $1.5B) remain stable. No insider trading or dividend/buyback activity reported; forward-looking catalysts cluster in late April-May closings and Q3 divestitures. Portfolio-level implications: Microcap distress outliers amid broader turnaround maneuvers, with dilution risks from equity raises but enhanced liquidity for 20+ companies signaling resilience over collapse.

37 high priority 37 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 15, 2026

Across 39 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq listing compliance crises in 4 small-cap biotechs/techs (Soluna, Alaunos, BioCardia, Mainz with equity deficits from $641k-$2.15M vs $2.5M min), high debt/concentration risks (Strawberry Fields REIT $752M debt, 86.8% rent from 15 leases), and deleveraging actions via asset sales (Spire $650M, Owens Corning $645M EV post-impairment), debt settlements (Visium $182k, SUNation $1.2M conversion), and equity raises (Graham $50M, Traws $10M PIPE). Credit facility amendments/extensions (Flowserve $1.45B, Federal Realty $1.4B, Leidos/U.S. Physical Therapy) signal proactive liquidity management amid potential distress, with no broad YoY revenue/margin declines but equity erosion in biotechs. Positive M&A/JVs (Tilray Lyphe accretive 2027, Limoneira composting FY2027) offer turnaround plays. Portfolio-level: 12/39 show debt reduction/capital inflows vs 7 Nasdaq risks; implications: short Nasdaq non-compliant, long deleveraging industrials/utilities.

39 high priority 39 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 14, 2026

Across 36 filings in the USA Corporate Distress & Bankruptcy intelligence stream (24 new), overarching themes reveal a financing frenzy with 18+ companies securing debt/equity (e.g., $50M CareCloud facility, $550M Lucid investment) to stave off liquidity crunches, contrasted by acute distress signals like Hydrofarm's interest default and Beasley's $49M stockholders' deficit triggering Nasdaq compliance risks. Period-over-period trends are sparse but highlight deteriorations: SunPower's GAAP revenue down $8.8M to $300M YoY with gross margins compressing 600 bps to 43%, Hydrofarm's unpaid interest due Jan 31 2026, and no broad margin expansions despite revenue targets like XCF's $1B fuel rev goal. M&A/take-private activity surges with premiums (Avanos 72%, Globalstar $90/share option), signaling exit opportunities amid distress, while 6 filings show covenant-heavy loans/forbearances maturing 2026-2027. Capital allocation leans toward deleveraging (CareCloud pref redemption saving $3.2M ann dividends) vs reinvestment, with no buybacks/dividends noted. Forward catalysts cluster H2 2026 (Avanos close, urban-gro 10-K filing), implying near-term volatility. Portfolio-level, neutral/positive sentiment dominates (26/36), but mixed/negative in 6 cases flag deepening distress; actionable now: arbitrage M&A spreads, short Nasdaq-deficient names.

36 high priority 36 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 13, 2026

The 31 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in liquidity-seeking actions amid compliance pressures, with 6 companies (ClearOne, Veea, Sow Good, Twin Vee, Wheeler, Trinseo) facing Nasdaq listing deficiencies or delistings based on recent 10-K equity shortfalls and bid price failures, signaling widespread balance sheet weakness. Debt restructurings dominate positively (10 filings including Marathon Petroleum $5B revolver, AdaptHealth $1.1B facility at lower spreads, MPLX $2.5B), extending maturities and boosting liquidity, though Trinseo's interest payment waivers highlight acute distress. Equity offerings and convertibles (Newton Golf $1.35M funded, Angel Studios $30M priced, ImageneBio $30M PIPE) provide near-term cash but risk dilution, while M&A like Somnigroup/Leggett $2.5B all-stock deal offers turnaround potential with $50M synergies. No broad YoY/QoQ revenue declines explicitly stated, but implied deterioration from equity drops below $2.5M-$15M thresholds and contract losses (Ameriguard 58% 2026 rev). Portfolio trend: Margin-neutral to compressed operations driving 4 lease terminations/cuts, but capital raises counterbalance; sector implication is heightened bankruptcy risk for microcaps vs investment-grade refinancings signaling resilience.

31 high priority 31 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 10, 2026

Across 35 8-K filings in the USA Corporate Distress & Bankruptcy stream (April 10, 2026 period), distress signals dominate with 8 companies facing Nasdaq delisting risks due to sub-$1 bid prices (e.g., DevvStream, Beyond Air, SCWorx), low stockholders' equity (Caring Brands, Callan JMB), or MVLS/net income failures (Alpha Modus), reflecting microcap vulnerability amid no explicit YoY/QoQ declines but inferred weak performance from compliance breaches post-reverse splits. Countervailing trends include 12+ capital raises/ATM offerings/debt amendments (e.g., Spire Global $70M PP, Annovis $10M offering, CoreCivic revolver to $400M), signaling aggressive liquidity pursuits to avert bankruptcy. No outright bankruptcies or going-concern warnings, but lease terminations (Lyra Therapeutics $4.4M cost) and deal terminations (Dynamix SPAC) highlight cost-cutting/restructuring. Positive outliers like Hecla Mining's $263M debt redemption and Venture Global's $1.75B refinancing unlock flexibility, while mixed sentiments prevail (14/35 neutral/mixed). Portfolio-level pattern: 40% filings show financing activity vs. 23% delisting risks, with no insider trading or dividend/buyback data but forward catalysts clustered April 10-15 closings. Implications: Short-term volatility in Nasdaq microcaps; opportunities in refinancings for turnaround plays.

35 high priority 35 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 09, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, a bifurcated picture emerges: 6 companies face acute Nasdaq listing risks (delistings, bid price, equity, assets/revenue deficiencies), signaling heightened distress in small-cap biotech/tech sectors, while 12 feature capital raises (offerings, notes, ATM) and 5 M&A/sale deals providing liquidity relief. No explicit YoY/QoQ revenue declines or margin compressions noted, but reverse splits in 3 firms (Actelis prior, Mobix, Quince) and dilutive financings (e.g., Intrusion $3.2M note, Prairie warrant dilution) highlight cash burn pressures; positive offsets include REIT acquisitions at 12-26% premiums and biotech partnerships unlocking $1B+ milestones. Portfolio-level trends show 70% neutral/positive sentiment, with distress concentrated in Nasdaq-deficient firms (avg materiality 9/10); forward catalysts cluster in Q2-Q3 2026 (closings, compliance deadlines). M&A (e.g., Whitestone $1.7B, Assertio $125M) offers exit premiums amid distress, but delisting risks (Actelis immediate) demand vigilance. Implications: Opportunistic M&A in REITs/energy, avoid Nasdaq-at-risk biotechs unless compliance plans succeed.

31 high priority 31 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 08, 2026

The 22 filings in the USA Corporate Distress & Bankruptcy stream reveal a landscape dominated by liquidity-seeking maneuvers, with 6 companies pursuing dilutive equity raises (ATM offerings, convertible preferred stock) totaling over $100M in capacity, signaling cash burn pressures in microcaps despite no outright bankruptcies. Distress signals are concentrated: SPAR Group's stockholders' equity at $622K vs. $2.5M Nasdaq minimum (Dec 31, 2025), KBS REIT III's explicit going concern doubt tied to $160.4M loan maturities by Dec 2026, Bitcoin Depot's $3.665M cyber theft loss, and Mosaic's $350-400M Q1 2026 Brazil impairment. Counterbalancing positives include M&A-driven growth (Catalyst Bancorp doubling assets to $627M, 180% EPS accretive; Odyssey Marine's $1B pro forma merger with $175M cash at close) and debt extensions (Dominion to 2031, Dover 5-year revolver). Sentiment skews positive/neutral (18/22), but materiality clusters around 8-10/10 for key risks/opportunities. No broad YoY/QoQ declines reported across filings, but asset sales (KBS $48.1M net) and idlings highlight operational retrenchment. Portfolio implication: Avoid pure distress plays like SPAR/KBS; favor consolidators like Catalyst/Odyssey for turnaround alpha.

22 high priority 22 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 07, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream spanning 29 filings (22 new), a bifurcated landscape emerges: acute distress in 6 cases including Luminar Technologies' confirmed Chapter 11 liquidation plan, Nasdaq delisting threats for Hydrofarm (-$63M equity deficit) and Direct Digital (-$7M deficit), Americas CarMart closing 42/136 stores with $14M impairment, Genie Energy's NYSE noncompliance from delayed 10-K restatements, and WM Technology's voluntary Nasdaq delisting; contrasted by 12 positive liquidity events averaging ~$60M each, notably Opus Genetics' $155M non-dilutive funding extending runway to 2029, Kiora Pharmaceuticals' $24M placement, Four Corners Property Trust's $200M loan at 5.4x leverage, and New Fortress Energy's $266M sale-leaseback. No widespread period-over-period declines reported across filings, but equity deficits highlight small-cap balance sheet frailties vs minimum thresholds ($2.5M Nasdaq). Biotech sector shines with 4/5 filings showing funding/runway extensions amid clinical catalysts (e.g., OPGx-BEST1 topline mid-2026), while energy/REITs amend/extend debt facilities positively. Capital allocation leans toward debt raises over returns, with no dividends/buybacks noted; insider activity sparse but Boxlight's related-party conversion flags potential conflicts. Forward-looking catalysts cluster in Q2 2026 (trials, closings, compliance deadlines), signaling near-term volatility for distressed names but alpha in turnarounds.

29 high priority 29 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — April 07, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical filing from Luminar Technologies, Inc., where the U.S. Bankruptcy Court for the Southern District of Texas confirmed the Fourth Amended Chapter 11 Plan of Liquidation on April 3, 2026, following a hearing on April 1, 2026, with all objections overruled. This marks the end of operations as debtors in possession since voluntary petitions filed on December 15 and 31, 2025, under Case No. 25-90807, proceeding directly to asset liquidation with no ongoing business highlighted. No period-over-period financial trends are available in the filing, but the shift to liquidation implies severe prior deterioration in financial health, liquidity, and operational viability. Sentiment is uniformly negative (10/10 materiality), signaling total equity wipeout risk and creditor priority in distributions. Portfolio-level theme across 1/1 filings: acceleration of tech sector insolvencies into structured liquidations, bearish for shareholders and bullish for short positions or distressed debt plays. Market implications include imminent delisting pressure, zero recovery for common stock, and potential fire-sale asset opportunities for competitors in lidar/autonomous vehicle tech.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 06, 2026

Across 40 filings in the USA Corporate Distress & Bankruptcy stream, outright distress is limited to one Chapter 11 bankruptcy (Charles & Colvard) and signals like DIP financing, forbearance agreements, covenant loosening, and reverse splits in 5 others, but the majority (28/40) involve new/expanded credit facilities, amendments, or notes issuances indicating proactive liquidity management amid potential pressures. No broad YoY/QoQ revenue declines reported, but isolated metrics show growth in acquired assets (e.g., VYKAT XR $190M 2025 revenue, INGREZZA $2.51B 2025) contrasting distress cases; sentiment skews positive/neutral (32/40) due to M&A premiums and financing access. Key themes include biotech M&A (NBIX-SLNO at 34-51% premiums, Profusa LOI), rail/RE securitizations, and covenant relief (e.g., Martin Midstream ICR to 1.65x, leverage to 5.5x). Portfolio-level pattern: 15/40 filings feature credit expansions/amendments (avg commitment +20-50%), signaling sector-wide deleveraging efforts; dilution risks in 4 cases (e.g., Greenpro shares doubled). Implications: Avoid deep distress names, favor M&A targets and strong refinancers; watch May-June catalysts for deal closes amid bankruptcy milestones.

40 high priority 40 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 03, 2026

The 39 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in exchange compliance failures, with 5 companies (Aeries Technology, Twin Vee PowerCats, Matinas BioPharma, Arrive AI, AEON Biopharma) receiving delisting notices due to bid price, MVPHS/MVLS, and stockholders' equity deficits below $2M-$6M thresholds as of Dec 31, 2025, signaling acute distress in microcap/biotech names. Covenant waivers and amendments dominate (United Homes, Firefly Aerospace, Fluence Energy, KORU Medical), often tied to mergers or liquidity covenants, providing short-term relief but with strings like refinancing deadlines (e.g., May 31, 2026 for United Homes). Positive offsets include M&A (Aurinia/Kezar merger Q2 2026, Forian $68M buyout, Soluna wind farm acquisition), debt cancellations (Nukkleus $16M), and equity raises (Entera Bio $10M, Vivos $4M), though many are dilutive (Mobix Labs 15% discount convertible, Interactive Strength Series C issuance). No uniform YoY/QoQ trends due to event-driven filings, but recurring low equity ($4.83M Matinas vs $6M req, -$55M AEON) and reverse splits (FibroBiologics 1:20) highlight deteriorating balance sheets. Portfolio-level: 15/39 negative/mixed sentiment, clustered in biotechs/small caps; implications include elevated bankruptcy risk but alpha in merger-arbitrage and post-financing turnarounds.

39 high priority 39 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 02, 2026

Across 50 8-K filings in the USA Corporate Distress & Bankruptcy stream (39 new), distress signals dominate with 6 Nasdaq compliance failures (bid price/MVLS/audit committee deficiencies, extensions to Sep 2026), 4 reverse stock splits (1:20 to 1:25 ratios), 5+ debt forbearances/amendments/CRO appointments signaling liquidity crunches, and litigation settlements amid ongoing obligations. Counterbalancing positives include 10+ equity offerings/PP/IPOs raising $200M+ (e.g., $400M Caris loan, $42M Summit), debt exchanges/refinancings (e.g., Terra $25.6M secured notes), and M&A (Nuveen/PCAP acquisition Q2 2026). No explicit YoY/QoQ revenue/margin trends disclosed, but implied deteriorations from overadvances ($16M Borealis obligations), Nasdaq sub-$1 bids, and min cash covenants ($50M Caris). Portfolio-level: Small-cap biotechs/healthcare lead distress (12/50), with capital allocation skewed to dilutive raises vs dividends/buybacks (0 reported); insider activity limited to exec separations (#17 Cardiff $1.1M severance). Implications: Heightened bankruptcy risk in biotechs/SPACs, alpha in post-raise runways (e.g., OS Therapies to 2027), monitor Q2 catalysts like approvals/forbearance ends.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 01, 2026

Across 44 8-K filings in the USA Corporate Distress & Bankruptcy stream (28 new), the dominant theme is proactive liquidity enhancement via 22+ credit facility amendments, extensions, or increases (e.g., Primo Brands refin $3.09B, American Assets Trust rev to $500M), signaling lender confidence and low imminent distress despite the stream focus. No outright bankruptcies or going concern warnings; mild distress in TBHC Nasdaq MVPHS deficiency (delist risk Sept 2026) and Westwater's SK On contract termination. Positive capital allocation trends include consistent dividends (Armour $0.24/share Apr, Nuveen $0.170/share Apr 28) and equity raises/mergers (SharonAI $1.25BN TCV, Cyclerion/Korsana). Period trends sparse but highlight modest fund returns (Nuveen Churchill Class I: 0.21% 1-mo, 0.74% YTD as of Feb 2026) vs stable REIT payouts; no broad YoY/QoQ declines. Forward catalysts cluster in Q2-Q3 2026 (merger closes, production ramps). Portfolio implication: Sector resilient, favoring liquidity plays over distress shorts; monitor delist/termination outliers for alpha.

44 high priority 44 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 31, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (42 new), outright distress is limited to 2 Chapter 11/7 bankruptcies (Lipella Pharmaceuticals, IO Biotech), 1 Nasdaq delisting with Irish winding-up (Iterum Therapeutics), 1 Nasdaq deficiency notice (Snail Inc.), and 1 asset sale leading to dissolution (Allbirds), concentrated in small-cap biotechs signaling sector fragility amid cash burn. However, 25+ filings detail proactive refinancings, new credit facilities (e.g., Prologis $B-scale global credit, Ares 3-yr term loan, Lincoln National $2B revolver), and equity raises (e.g., Satellogic $50M ATM, SCYNEXIS $40M placement), indicating liquidity bolstering to avert distress rather than collapse. Period-over-period trends show mixed revenue performance: nCino +6% Q4/+10% FY revenues to $594.8M with GAAP profitability turn ($5.2M FY NI vs -$37.9M prior); Purple +9.1% Q4 rev but -3.9% FY to $468.7M, EBITDA to +$1.9M from -$20.8M. Forward-looking catalysts include Q2 2026 M&A closes (Repay-KUBRA $372M, Allbirds $39M sale), nCino FY2027 rev guidance $639-643M (+8% at midpoint), and biotech approvals (SCYNEXIS Phase 2 data). Portfolio-level patterns reveal financing optimism (positive sentiment 20/50) vs biotech risks (negative/mixed 8/50), with capital allocation favoring debt/equity over buybacks/dividends, creating opportunities in stabilized microcaps but high short-term volatility risks.

50 high priority 50 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 31, 2026

Two biotech/pharma companies, Lipella Pharmaceuticals Inc. and IO Biotech, Inc., filed for bankruptcy within two days (March 30-31, 2026), signaling acute distress in the emerging growth biotech sector amid funding challenges and operational failures. Both filings carry maximal materiality (10/10) with uniformly negative sentiment, warning shareholders of highly speculative trading, substantial total loss risks, and no expected recoveries. No positive period-over-period trends evident; instead, implied severe deterioration led to Chapter 11 (Lipella, reorganization) and Chapter 7 (IO Biotech, liquidation) proceedings, with IO Biotech ceasing all operations, terminating staff/leadership, and defaulting on a €22.5M EIB loan. Key market implication: Nasdaq-listed IOBT and Lipella shares decouple from fundamentals, presenting extreme volatility and downside. Portfolio-level pattern: Cluster of insolvencies highlights biotech funding winter, with no capital allocation (dividends/buybacks), insider activity, or forward guidance beyond liquidation warnings.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 30, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (Mar 30, 2026 period), proactive liquidity management dominates with 25+ credit amendments/extensions/increases (e.g., Nexstar $1.75B Term B-7, Ares $350M facility to $400M accordion) signaling lender support amid distress risks. True distress limited to 1 Chapter 11 (Twin Hospitality governance overhaul), 7 Nasdaq/NYSE deficiencies/delisting threats (Dyadic equity <$2.5M, Greenlane post-multiple reverses), and reverse splits (agilon 1:25, Safe & Green 1:20). Positive asset sales for cash (Spire $215M gas marketing, Star Equity $1.69M properties) and equity raises (OnKure $150M, Capstone $112.5M) outpace negatives. No broad YoY/QoQ declines reported, but Spire cut FY27 EPS guidance to $5.40-$5.60 from $5.65-$5.85 despite FY26 affirm. Sentiment: 20 positive, 15 neutral/mixed, 8 negative; portfolio trend shows contained distress via refinancing, but small-cap Nasdaq risks elevated. Implications: Favor companies completing financings (e.g., closings 3/31/26) over compliance-challenged names.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 27, 2026

Across 47 filings in the USA Corporate Distress & Bankruptcy stream, a mix of distress signals and resilience emerges, with 9 companies (HAIN, Alight, ZW Data, SOPA, IMMERSION, BiomX, GIFTIFY, AMERICAN REBEL, BIOMX) facing Nasdaq/NYSE listing deficiencies primarily from sub-$1 bid prices over 30 days, alongside Iterum Therapeutics' bankruptcy petition, but offset by 20+ positive financings, refinancings, and M&A (e.g., TWO Harbors merger at $10.80/share, i-80 Gold $150M prepay). Period-over-period trends are sparse but highlight distress in Origin Materials (Q4 rev -67% YoY to $3M, FY rev -40% to $18.9M, op ex +1100% YoY Q4 due to $178.8M impairment) and covenant relaxations (OFS Capital tangible net assets covenant cut 25% to $75M). Portfolio-level patterns show small-cap biotechs/techs vulnerable to delistings (8/47), while energy/finance firms (Delek, Enterprise Products, Puget Energy) secure larger facilities ($450M-$1.5B), signaling sector rotation opportunities. Forward-looking catalysts cluster in April 2026 (Anaptys spin-off 4/20, Cartesian redemption pre-domestication, Nasdaq cures by Sep). Capital allocation leans defensive (dividends continued pre-merger at TWO, Immersion $0.075/share), with insider alignment via lockups (Streamex co-founders 1-yr voluntary). Overall, distress concentrated in microcaps, but refinancings indicate manageable liquidity for larger names, urging watch on compliance deadlines.

47 high priority 47 total filings